Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present? - 2Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- 3What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- 4I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.
- 5Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- French ship crosses Strait of Hormuz in first Western European transit during Iran war
- Revvity says it will exceed 2025 profit forecast range
- Financial plan Cordial Home Redesigns That Add Worth
- Careful Living: Embracing the Current Second
- France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown
- Astronomers detect black hole blasting winds at incredible speeds
- Israel reports first missile fire from Yemen since start of Iran war
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
